Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Zenas, a US-China Biopharma, Announces $480 Million Deal for Autoimmune Therapy

publication date: Nov 23, 2021

In a $480 million deal. Zenas BioPharma acquired global rights to a bifunctional antibody from Xencor that targets CD19. The candidate uses Xencor's XmAb® Immune Inhibitor Fc Domain to target FcγRIIb, a receptor that inhibits the function of B-cells, which function in the immune system. The candidate, obexelimab, is in pre-clinical development. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to acquire additional Zenas shares up to 15% of Zenas’ equity. Zenas will also pay $480 million in milestones plus royalties on sales. More details....

Stock Symbol: (NSDQ: XNCR) 

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China